ADAM28 is a serological and histochemical marker for non-small-cell lung cancers

Hiroaki Kuroda, Satsuki Mochizuki, Masayuki Shimoda, Miyuki Chijiiwa, Kazunori Kamiya, Yotaro Izumi, Masazumi Watanabe, Hirohisa Horinouchi, Masahumi Kawamura, Koichi Kobayashi, Yasunori Okada

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

ADAM28 (a disintegrin and metalloproteinase 28) is over-expressed in non-small-cell lung cancer (NSCLC) with correlation to cancer cell proliferation, tumor size and lymph node metastasis. The present study was aimed to develop an enzyme-linked immunosorbent assay (ELISA) system for diagnosis and monitoring of NSCLC. Our ELISA specifically measured ADAM28, showing negligible cross-reactivity with other metalloproteinases. The ADAM28 level in the NSCLC tissue was remarkably 36.9-fold higher than that in the non-neoplastic lung tissue (p < 0.001). The serum level was significantly 4.6-fold higher in the NSCLC patients (5.41 8.62 ng/ml; n = 102) than in the control subjects (1.17 0.93 ng/ml; n = 20) (p < 0.001), and increased with progress of tumor stage (p < 0.001). The level was also significantly higher in the patients with recurrent carcinoma than the control (p < 0.001) and in the patients with lymph node metastasis than those without metastasis (p < 0.001). The sensitivity, false-negative rate and AUC for ADAM28 were better than those for carcinoembryonic antigen. The combination of both assays improved the sensitivity, specificity, false-positive and false-negative rates for NSCLC. There was a positive correlation between the ADAM28 level measured by ELISA system and the degree of immunostaining in the lung adenocarcinomas with a size of &20 mm in diameter. The adenocarcinoma patients showing the high immunohistochemical reaction exhibited a poorer disease-free survival than those with the lower immunoreactivity (n = 102; p < 0.05). These data demonstrate that our ELISA is specific and sensitive to monitor the levels of ADAM28 in the samples from NSCLC patients and suggest that ADAM28 is a useful serological and histochemical marker for NSCLC.

Original languageEnglish
Pages (from-to)1844-1856
Number of pages13
JournalInternational Journal of Cancer
Volume127
Issue number8
DOIs
Publication statusPublished - 2010 Oct 15

Fingerprint

Disintegrins
Metalloproteases
Non-Small Cell Lung Carcinoma
Enzyme-Linked Immunosorbent Assay
Neoplasm Metastasis
Lymph Nodes
Neoplasms
Carcinoembryonic Antigen
Disease-Free Survival
Area Under Curve
Adenocarcinoma
Cell Proliferation
Carcinoma
Sensitivity and Specificity
Lung

Keywords

  • ADAM
  • biological marker
  • diagnosis
  • lung cancer
  • prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Kuroda, H., Mochizuki, S., Shimoda, M., Chijiiwa, M., Kamiya, K., Izumi, Y., ... Okada, Y. (2010). ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. International Journal of Cancer, 127(8), 1844-1856. https://doi.org/10.1002/ijc.25212

ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. / Kuroda, Hiroaki; Mochizuki, Satsuki; Shimoda, Masayuki; Chijiiwa, Miyuki; Kamiya, Kazunori; Izumi, Yotaro; Watanabe, Masazumi; Horinouchi, Hirohisa; Kawamura, Masahumi; Kobayashi, Koichi; Okada, Yasunori.

In: International Journal of Cancer, Vol. 127, No. 8, 15.10.2010, p. 1844-1856.

Research output: Contribution to journalArticle

Kuroda, H, Mochizuki, S, Shimoda, M, Chijiiwa, M, Kamiya, K, Izumi, Y, Watanabe, M, Horinouchi, H, Kawamura, M, Kobayashi, K & Okada, Y 2010, 'ADAM28 is a serological and histochemical marker for non-small-cell lung cancers', International Journal of Cancer, vol. 127, no. 8, pp. 1844-1856. https://doi.org/10.1002/ijc.25212
Kuroda, Hiroaki ; Mochizuki, Satsuki ; Shimoda, Masayuki ; Chijiiwa, Miyuki ; Kamiya, Kazunori ; Izumi, Yotaro ; Watanabe, Masazumi ; Horinouchi, Hirohisa ; Kawamura, Masahumi ; Kobayashi, Koichi ; Okada, Yasunori. / ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. In: International Journal of Cancer. 2010 ; Vol. 127, No. 8. pp. 1844-1856.
@article{ccaec10329f149fe95198ea4f9da365e,
title = "ADAM28 is a serological and histochemical marker for non-small-cell lung cancers",
abstract = "ADAM28 (a disintegrin and metalloproteinase 28) is over-expressed in non-small-cell lung cancer (NSCLC) with correlation to cancer cell proliferation, tumor size and lymph node metastasis. The present study was aimed to develop an enzyme-linked immunosorbent assay (ELISA) system for diagnosis and monitoring of NSCLC. Our ELISA specifically measured ADAM28, showing negligible cross-reactivity with other metalloproteinases. The ADAM28 level in the NSCLC tissue was remarkably 36.9-fold higher than that in the non-neoplastic lung tissue (p < 0.001). The serum level was significantly 4.6-fold higher in the NSCLC patients (5.41 8.62 ng/ml; n = 102) than in the control subjects (1.17 0.93 ng/ml; n = 20) (p < 0.001), and increased with progress of tumor stage (p < 0.001). The level was also significantly higher in the patients with recurrent carcinoma than the control (p < 0.001) and in the patients with lymph node metastasis than those without metastasis (p < 0.001). The sensitivity, false-negative rate and AUC for ADAM28 were better than those for carcinoembryonic antigen. The combination of both assays improved the sensitivity, specificity, false-positive and false-negative rates for NSCLC. There was a positive correlation between the ADAM28 level measured by ELISA system and the degree of immunostaining in the lung adenocarcinomas with a size of &20 mm in diameter. The adenocarcinoma patients showing the high immunohistochemical reaction exhibited a poorer disease-free survival than those with the lower immunoreactivity (n = 102; p < 0.05). These data demonstrate that our ELISA is specific and sensitive to monitor the levels of ADAM28 in the samples from NSCLC patients and suggest that ADAM28 is a useful serological and histochemical marker for NSCLC.",
keywords = "ADAM, biological marker, diagnosis, lung cancer, prognosis",
author = "Hiroaki Kuroda and Satsuki Mochizuki and Masayuki Shimoda and Miyuki Chijiiwa and Kazunori Kamiya and Yotaro Izumi and Masazumi Watanabe and Hirohisa Horinouchi and Masahumi Kawamura and Koichi Kobayashi and Yasunori Okada",
year = "2010",
month = "10",
day = "15",
doi = "10.1002/ijc.25212",
language = "English",
volume = "127",
pages = "1844--1856",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - ADAM28 is a serological and histochemical marker for non-small-cell lung cancers

AU - Kuroda, Hiroaki

AU - Mochizuki, Satsuki

AU - Shimoda, Masayuki

AU - Chijiiwa, Miyuki

AU - Kamiya, Kazunori

AU - Izumi, Yotaro

AU - Watanabe, Masazumi

AU - Horinouchi, Hirohisa

AU - Kawamura, Masahumi

AU - Kobayashi, Koichi

AU - Okada, Yasunori

PY - 2010/10/15

Y1 - 2010/10/15

N2 - ADAM28 (a disintegrin and metalloproteinase 28) is over-expressed in non-small-cell lung cancer (NSCLC) with correlation to cancer cell proliferation, tumor size and lymph node metastasis. The present study was aimed to develop an enzyme-linked immunosorbent assay (ELISA) system for diagnosis and monitoring of NSCLC. Our ELISA specifically measured ADAM28, showing negligible cross-reactivity with other metalloproteinases. The ADAM28 level in the NSCLC tissue was remarkably 36.9-fold higher than that in the non-neoplastic lung tissue (p < 0.001). The serum level was significantly 4.6-fold higher in the NSCLC patients (5.41 8.62 ng/ml; n = 102) than in the control subjects (1.17 0.93 ng/ml; n = 20) (p < 0.001), and increased with progress of tumor stage (p < 0.001). The level was also significantly higher in the patients with recurrent carcinoma than the control (p < 0.001) and in the patients with lymph node metastasis than those without metastasis (p < 0.001). The sensitivity, false-negative rate and AUC for ADAM28 were better than those for carcinoembryonic antigen. The combination of both assays improved the sensitivity, specificity, false-positive and false-negative rates for NSCLC. There was a positive correlation between the ADAM28 level measured by ELISA system and the degree of immunostaining in the lung adenocarcinomas with a size of &20 mm in diameter. The adenocarcinoma patients showing the high immunohistochemical reaction exhibited a poorer disease-free survival than those with the lower immunoreactivity (n = 102; p < 0.05). These data demonstrate that our ELISA is specific and sensitive to monitor the levels of ADAM28 in the samples from NSCLC patients and suggest that ADAM28 is a useful serological and histochemical marker for NSCLC.

AB - ADAM28 (a disintegrin and metalloproteinase 28) is over-expressed in non-small-cell lung cancer (NSCLC) with correlation to cancer cell proliferation, tumor size and lymph node metastasis. The present study was aimed to develop an enzyme-linked immunosorbent assay (ELISA) system for diagnosis and monitoring of NSCLC. Our ELISA specifically measured ADAM28, showing negligible cross-reactivity with other metalloproteinases. The ADAM28 level in the NSCLC tissue was remarkably 36.9-fold higher than that in the non-neoplastic lung tissue (p < 0.001). The serum level was significantly 4.6-fold higher in the NSCLC patients (5.41 8.62 ng/ml; n = 102) than in the control subjects (1.17 0.93 ng/ml; n = 20) (p < 0.001), and increased with progress of tumor stage (p < 0.001). The level was also significantly higher in the patients with recurrent carcinoma than the control (p < 0.001) and in the patients with lymph node metastasis than those without metastasis (p < 0.001). The sensitivity, false-negative rate and AUC for ADAM28 were better than those for carcinoembryonic antigen. The combination of both assays improved the sensitivity, specificity, false-positive and false-negative rates for NSCLC. There was a positive correlation between the ADAM28 level measured by ELISA system and the degree of immunostaining in the lung adenocarcinomas with a size of &20 mm in diameter. The adenocarcinoma patients showing the high immunohistochemical reaction exhibited a poorer disease-free survival than those with the lower immunoreactivity (n = 102; p < 0.05). These data demonstrate that our ELISA is specific and sensitive to monitor the levels of ADAM28 in the samples from NSCLC patients and suggest that ADAM28 is a useful serological and histochemical marker for NSCLC.

KW - ADAM

KW - biological marker

KW - diagnosis

KW - lung cancer

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=77956987886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956987886&partnerID=8YFLogxK

U2 - 10.1002/ijc.25212

DO - 10.1002/ijc.25212

M3 - Article

VL - 127

SP - 1844

EP - 1856

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 8

ER -